Cargando…

Corrigendum to “Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine” [Clinical Immunology 237 (2022) 108963]

Detalles Bibliográficos
Autores principales:	Wong, Matthew K., Liu, Jun T., Budylowksi, Patrick, Yue, Feng Yun, Li, Zhijie, Rini, James M., Carlyle, James R., Zia, Amin, Ostrowski, Mario, Martin, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2023
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155827/ https://www.ncbi.nlm.nih.gov/pubmed/37147236 http://dx.doi.org/10.1016/j.clim.2023.109246

Ejemplares similares

Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine
por: Wong, Matthew K., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients
por: Fu, Jia, et al.
Publicado: (2022)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
por: Hurme, Antti, et al.
Publicado: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months
por: Low, Ee Vien, et al.
Publicado: (2022)

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022)

Homology modeling, comparative genomics and functional annotation of Mycoplasma genitalium hypothetical protein MG_237
por: Butt, Azeem Mehmood, et al.
Publicado: (2011)

Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination
por: Bauswein, Markus, et al.
Publicado: (2022)

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART
por: Gianserra, Laura, et al.
Publicado: (2022)

BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents
por: Jahrsdörfer, Bernd, et al.
Publicado: (2021)

Oral Presentations 208–237
Publicado: (2001)

Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2
por: Au, Lewis, et al.
Publicado: (2021)

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
por: Favresse, Julien, et al.
Publicado: (2022)

Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

A Longitudinal Study in Turkiye of Host Ability to Produce Antibodies following a Third Homologous BNT162b2 Vaccination
por: Erdem, Mustafa Genco, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals
por: Luczkowiak, Joanna, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
por: Hung Nguyen, Van, et al.
Publicado: (2023)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
por: Janssen, Cécile, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19
por: Kim, Dong-In, et al.
Publicado: (2022)

Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England
por: Mason, Thomas F. D., et al.
Publicado: (2021)

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
por: Priddy, Frances H., et al.
Publicado: (2022)

Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
por: Luczkowiak, Joanna, et al.
Publicado: (2021)

Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
por: Skrzat-Klapaczyńska, Agata, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Health Tract, No. 237: Foul Odors
Publicado: (1866)

Cannot write session to /tmp/vufind_sessions/sess_j44h7s4b5i34jnc015d4ibjvmk